← Eichor
Study identifier: NCT06801834 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Condition: Extensive Stage Small Cell Lung Cancer (ES-SCLC)  ·  Sponsor: Gilead Sciences

PhasePhase 3
Planned participants695
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on overall survival (OS).

This description comes directly from the study's public registry record.

Talk to the study team

Gilead Clinical Study Information Cente  ·  1-833-445-3230 (GILEAD-0)  ·  GileadClinicalTrials@gilead.com

Always discuss trial participation with your own doctor first.

Locations (218)

Genesis Cancer and Blood InstituteHot Springs, Arkansas, United StatesRecruiting
Los Angeles Cancer NetworkAnaheim, California, United StatesRecruiting
Boca Raton RegionalMiami, Florida, United StatesRecruiting
Hope and Healing Cancer ServicesHinsdale, Illinois, United StatesRecruiting
Southern Illinois University School of MedicineSpringfield, Illinois, United StatesRecruiting
Springfield ClinicSpringfield, Illinois, United StatesRecruiting
Parkview Research CenterFort Wayne, Indiana, United StatesRecruiting
IU Health Ball Memorial Hospital and Physicians - Cancer Center - MuncieMuncie, Indiana, United StatesRecruiting
Northwest Cancer CentersDyer, Kentucky, United StatesRecruiting
St. Claire Regional Medical CeMorehead, Kentucky, United StatesRecruiting
Maine Health Cancer CareScarborough, Maine, United StatesNot Yet Recruiting
Optum Care Cancer CareLas Vegas, Nevada, United StatesNot Yet Recruiting

+ 206 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06801834